Ascletis Pharma's (HKG:1672) loss attributable to equity shareholders came in at 359.9 million yuan for 2025, widening 20% from 300.9 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.
Shares of the pharmaceutical firm were up over 5% in Wednesday's midday trade.
Loss per share came in at 0.3701 yuan, compared with 0.3005 yuan in the prior year.
Total income rose 5.2% to 127.4 million yuan from 121.1 million yuan in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments